Table 4. Summary of adverse events.

	STA-2 group (n = 39)	Placebo group (n = 40)
	N (%)	N (%)
Total AEs	32	33
Patients with AEs	17 (44%)	18 (45%)
Patients with SAEs	0	1 (3%)
Patients with treatment-related AEs	6 (15%)	1 (3%)
Most commonly reported AEs
Palpitations	2 (5%)	0
Abdominal distension	0	3 (8%)
Upper abdominal pain	2 (5%)	0
Chest discomfort	1 (3%)	2 (5%)
Chest pain	2 (5%)	0
Upper respiratory tract infection	2 (5%)	1 (3%)
Hypertriglyceridemia	0	2 (5%)
Spinal osteoarthritis	0	2 (5%)
Insomnia	2 (5%)	0
Renal impairment	0	2 (5%)

AE, adverse event; SAE, serious adverse event.